# Genmab

Type: Company (GMAB)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/genmab
Canonical HTML page: https://getbiobrief.com/entity/genmab

## Timeline

- **2026-07-23**: Clarification on US Primary Endpoint — Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
- **2026-06-12**: EHA 2026 Presentation — Additional study results presented at the European Hematology Association Congress.
- **2026-01-16**: Topline Results Announced — Genmab and AbbVie released initial data from the Phase 3 EPCORE DLBCL-1 trial.

## Recent coverage (2 stories)

### Epcoritamab Phase 3 OS Miss Clouds $300M Revenue Stream for AbbVie and Genmab
2026-08-01 11:31:26 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its US overall survival endpoint, jeopardizing full approval and the drug's growing $300 million annual sales. This clarification deepens the competitive threat from other bispecifics with survival data.
Full story: https://getbiobrief.com/story/epcoritamab-phase3-os-miss-revenue-risk

### Epcoritamab-Lenalidomide Hits Phase 3 PFS Goals: 60% Risk Reduction
2026-07-11 23:08:27 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 3

AbbVie and Genmab's bispecific antibody epcoritamab combined with lenalidomide delivered a hazard ratio of 0.40 in a pivotal DLBCL trial, setting the stage for regulatory filings and a potential second-line market expansion that could challenge CAR-T dominance and redefine the bispecific landscape.
Full story: https://getbiobrief.com/story/epcoritamab-lenalidomide-phase3-dlbcl-biotech-abbv-gmab

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.